Paolo Paoletti, MD

Paolo Paoletti, MD has a diverse work experience, holding various roles in different companies. Paolo is currently working as the CEO of GammaDelta Therapeutics since March 2017. Prior to this, they served as a Member of the Board for FORMA Therapeutics, Genmab, NuCana BioMed Ltd, Psioxus Therapeutics, and Kesios Therapeutics. In their role at Kesios Therapeutics, they were the CEO from November 2015 to January 2017. Before joining GammaDelta Therapeutics and these board positions, Paolo Paoletti worked at GSK as the President of the Oncology Business Unit from January 2011 to April 2015.

Paolo Paoletti, MD attended the Università di Pisa, where they obtained a Doctor of Medicine (MD) degree in the field of Medicine.